Viridian Therapeutics (VRDN) Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye Disease Oct 26, 2023 08:06AM
Viridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye Disease Oct 26, 2023 08:00AM
Viridian Therapeutics (VRDN) Appoints Sarah Gheuens to its Board Sep 25, 2023 08:02AM
Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors Sep 25, 2023 08:00AM
Viridian Therapeutics Announces Presentations at Multiple Medical Meetings in September Sep 7, 2023 08:00AM


Aug 8, 2023 04:01PM Viridian Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Jun 13, 2023 08:00AM Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Endocrine Society
Jun 5, 2023 04:05PM Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 9, 2023 04:01PM Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 8, 2023 08:00AM Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections
May 4, 2023 04:05PM Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 2, 2023 08:00AM Viridian Therapeutics to Webcast First Quarter 2023 Financial Results and Corporate Update on May 9, 2023
Apr 12, 2023 08:03AM Viridian Therapeutics (VRDN) Appoints Tony Casciano as Chief Commercial Officer
Apr 12, 2023 08:00AM Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer
Aug 11, 2021 07:00AM Viridian Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
Aug 5, 2021 08:30AM Viridian Therapeutics to Participate in the Wedbush PacGrow Healthcare Virtual Conference
Jul 26, 2021 07:32AM Viridian Therapeutics (VRDN) Appoints Kristian Humer as CFO and CBO
Jul 26, 2021 07:30AM Viridian Therapeutics Appoints Kristian Humer as Chief Financial Officer and Chief Business Officer
Jul 15, 2021 04:05PM Viridian Therapeutics Appoints Jennifer Moses, CPA to the Board of Directors and as Chair of the Audit Committee
Jul 14, 2021 08:00AM Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jul 7, 2021 08:00AM Viridian Therapeutics to Present at the Ladenburg Thalmann 2021 Healthcare Conference
Jun 10, 2021 08:00AM Viridian Therapeutics to Participate in the JMP Securities Life Sciences Conference
May 14, 2021 08:00AM Viridian Therapeutics to Participate in Upcoming Investor Conferences
May 6, 2021 04:05PM Viridian Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Updates
Mar 25, 2021 04:05PM Viridian Therapeutics Reports 2020 Financial Results and Provides Corporate Updates
Mar 23, 2021 04:00AM Zenas BioPharma Launches as a Cross-Border Biopharmaceutical Company to Bring Innovation to the Development and Delivery of Immune-Based Therapies
Mar 23, 2021 04:00AM Lancement de Zenas BioPharma, société biopharmaceutique transfrontalière qui innove dans le développement et la fourniture de traitements immunitaires
Mar 23, 2021 04:00AM Zenas BioPharma Launches as a Cross-Border Biopharmaceutical Company to Bring Innovation to the Development and Delivery of Immune-Based Therapies
Mar 9, 2021 04:30PM Viridian Therapeutics To Host Conference Call Discussing Fourth Quarter And Full Year 2020 Results And Corporate Update
Feb 22, 2021 08:00AM Viridian Therapeutics to Present at Three Upcoming Investor Conferences
Jan 19, 2021 07:00AM miRagen Therapeutics Announces Company Name Change to Viridian Therapeutics and New Executive Appointments, Including Expansion of Leadership Team